| 1 |
NCT03559088 |
Recruiting |
A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care |
|
|
Interventional
|
Not Applicable |
- Eli Lilly and Company
- Atrium Health
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Number of Participants Receiving a Preventive Migraine Prescription
- Number of Months of App Use
- Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates
- (and 6 more...)
|
200 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03559088 |
17129
I5Q-MC-CGBA |
|
June 11, 2018 |
July 18, 2019 |
July 18, 2020 |
June 15, 2018 |
September 21, 2018 |
|
- Charlotte Medical Clinic
Charlotte, North Carolina, United States - Charlotte Internal Medicine
Charlotte, North Carolina, United States - Charlotte Medical Group
Charlotte, North Carolina, United States - (and 2 more...)
|
|
| 2 |
NCT02695498 |
Recruiting |
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines |
|
- Other: Mindfulness Based Stress Reduction
- Other: Migraine/stress Education
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in frequency of migraine days from baseline
- Change in migraine duration from baseline
- Change in migraine severity-pain intensity from baseline
- (and 22 more...)
|
98 |
All |
18 Years and older (Adult, Older Adult) |
NCT02695498 |
K23AT008406 |
|
March 2016 |
May 2019 |
June 2019 |
March 1, 2016 |
July 18, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 3 |
NCT03395457 |
Not yet recruiting |
Tertiary Care With or Without Manual Therapy for Chronic Migraine |
|
- Drug: Care as usual
- Other: Manual Therapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in migraine-related disability
- Change in Migraine Specific Quality of Life Questionnaire Score (MSQoL 2.1)
- Headache Frequency
|
70 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03395457 |
Bournemouth 228901 |
|
August 13, 2018 |
December 1, 2018 |
December 1, 2018 |
January 10, 2018 |
July 11, 2018 |
|
|
|
| 4 |
NCT03381924 |
Completed |
Educational Intervention in Patients With Migraine |
|
- Other: Educational programme
- Other: Routine clinical practice
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine-related disability given by the MIDAS score
- Intensity and frequency of the pain
- Degree to which activities of daily life were limited by migraine
- costs associated with migraine-related treatment
|
116 |
All |
Child, Adult, Older Adult |
NCT03381924 |
MIGRAINE01 |
M01 |
August 1, 2013 |
May 30, 2016 |
May 30, 2016 |
December 22, 2017 |
December 22, 2017 |
|
- Iñaki Aguirrezabal Bazterrica
Vitoria-gasteiz, Alava, Spain
|
|
| 5 |
NCT02570633 |
Unknown † |
Ginger Capsules for the Prophylactic Treatment of Migraine |
|
- Other: Extract of ginger
- Other: Cellulose
|
Interventional
|
Not Applicable |
- Federal University of Minas Gerais
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the frequency of migraine attacks.
- Change in migraine impact in the last month.
- Change in migraine impact in the last three months.
- Changes in the serum levels of biomarkers.
|
104 |
All |
18 Years to 60 Years (Adult) |
NCT02570633 |
CAAE 28236814.3.0000.5149 |
|
July 2014 |
September 2016 |
January 2017 |
October 7, 2015 |
March 25, 2016 |
|
- Ambulatório Bias Fortes
Belo Horizonte, Minas Gerais, Brazil
|
|
| 6 |
NCT03026101 |
Recruiting |
Understanding the Pathophysiology of Migraine Pain |
- Migraine Disorders
- Migraine, Classic
- Migraine Without Aura
|
|
Interventional
|
Not Applicable |
- Montefiore Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Migraine
- Migraine log pre-procedure: severity measure
- Migraine log pre-procedure: frequency measure
- (and 17 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03026101 |
2017-8335 |
|
January 2017 |
January 2019 |
June 2019 |
January 20, 2017 |
April 24, 2018 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 7 |
NCT02703129 |
Completed |
Nutritional Intervention in Migraine |
|
- Other: Nutritional intervention
|
Interventional
|
Not Applicable |
- Federal University of Minas Gerais
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in clinical parameters of migraine patients by nutritional intervention in the last month.
- Change in clinical parameters of migraine patients by nutritional intervention in the last three month.
- Change in diet quality of migraine patients by nutritional intervention assessed with the Brazilian Healthy Eating Index - Revised (BHEI-R)
- Change in depressive symptoms in migraine patients by nutritional intervention assessed with the Beck Depression Inventory (BDI)
|
52 |
|
Child, Adult, Older Adult |
NCT02703129 |
CAAE 0311.0.203.000-11 |
|
January 2010 |
December 2012 |
December 2012 |
March 9, 2016 |
March 9, 2016 |
|
- Ambulatório Bias Fortes
Belo Horizonte, Minas Gerais, Brazil
|
|
| 8 |
NCT03555214 |
Completed |
Efficacy of Manual Therapy for the Treatment of Migraine. |
|
- Other: Manual Therapy Group
- Other: Control group
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Intensity of Pain
- Frequency of pain
- Disability
- (and 5 more...)
|
33 |
All |
18 Years to 60 Years (Adult) |
NCT03555214 |
ID0024 |
MT-Migraine |
May 31, 2018 |
June 30, 2018 |
July 15, 2018 |
June 13, 2018 |
August 20, 2018 |
|
- Faculty of Physiotherapy
Valencia, Spain
|
|
| 9 |
NCT03361423 |
Active, not recruiting |
Evaluation of a Novel Device for Treatment of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Device: Nerivio Migra-1 active device
- Device: Nerivio Migra-1 Sham device
|
Interventional
|
Not Applicable |
- Theranica
- Rambam Health Care Campus
- Northwell Health
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of reduction of migraine headache post 2 hours from treatment
- Percentage of reduction of most bothersome migraine-associated symptom (MBS) relief post 2 hours treatment
- Percentage of reduced Migraine Headache AND MBS Relief post 2 hours post tresatment
- Percentage of pain disappearance 2 hours post treatment
|
296 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03361423 |
TCH003 |
|
December 17, 2017 |
October 30, 2018 |
January 30, 2019 |
December 4, 2017 |
August 21, 2018 |
|
- Hartford Headache Center
Hartford, Connecticut, United States - Mercy Hospital
Saint Louis, Missouri, United States - Clinvest Research
Springfield, Missouri, United States - (and 9 more...)
|
|
| 10 |
NCT03166046 |
Completed |
Migraine Prevention Using ActiPatch |
|
- Device: Pulsed Shortwave Therapy
- Device: Placebo Pulsed Shortwave therapy
|
Interventional
|
Not Applicable |
- BioElectronics Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine frequency
- Migraine duration
- Migraine intensity measured with Visual Analogue Pain Score
- Headache disability measured with Headache Impact Test
|
45 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03166046 |
SAIRB-17-0021 |
PSWT |
June 1, 2017 |
April 1, 2018 |
April 30, 2018 |
May 24, 2017 |
August 2, 2018 |
|
- Eppley Group
Indianapolis, Indiana, United States
|
|
| 11 |
NCT01294046 |
Completed
Has Results |
Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches |
|
- Device: Deep Brain Stimulation of SPG for Migraine
|
Interventional
|
Not Applicable |
- The Cleveland Clinic
- Autonomic Technologies, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine Relief at 2 Hours Post Stimulation
- Migraine Free at 2 Hours
- Pain Free at 2 Hours Post Stimulation
- (and 7 more...)
|
3 |
All |
18 Years and older (Adult, Older Adult) |
NCT01294046 |
IDE Number : G100007 |
|
March 2011 |
March 2014 |
March 2014 |
February 11, 2011 |
April 14, 2017 |
March 7, 2017 |
- Cleveland Clinic
Cleveland, Ohio, United States
|
|
| 12 |
NCT02443519 |
Recruiting |
Bronx MBCT-Migraine |
|
- Behavioral: MBCT for Migraine
|
Interventional
|
Not Applicable |
- Albert Einstein College of Medicine, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment
- Headache-Related Disability Index
- Headache Days (over course of 1 month)
- (and 9 more...)
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02443519 |
2015-4684 |
BMBCT-M |
May 2015 |
September 2018 |
July 2019 |
May 14, 2015 |
January 16, 2018 |
|
- Yeshiva University
Bronx, New York, United States
|
|
| 13 |
NCT03220113 |
Recruiting |
Treatment of Chronic Migraine Headaches. |
- Chronic Migraine Without Aura, Intractable
- Migraine With Typical Aura
- Migraine Disorders
|
- Combination Product: Dexamethasone, Lidocaine, Thiamine cohort
|
Interventional
|
Phase 1
Phase 2 |
- Corona Doctors Medical Clinics, Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of the safety to the De-Novo treatment formula in study patients
- Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure
|
100 |
All |
10 Years to 90 Years (Child, Adult, Older Adult) |
NCT03220113 |
2017/05/1 |
Migraine |
July 1, 2017 |
July 1, 2018 |
July 1, 2019 |
July 18, 2017 |
April 4, 2018 |
|
- Corona Doctors Medical Clinics Inc
Corona, California, United States
|
|
| 14 |
NCT03097536 |
Recruiting |
Migraine and Homeostasis:What Can we Learn From Glucose |
|
|
Interventional
|
Not Applicable |
- Beth Israel Deaconess Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The difference in blood glucose on days with migraine compared to blood glucose on days without migraine
- The primary outcome is the change in pain score from the time of pain plateau to the pain score at 120 minutes as measured by a visual analogue scale.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03097536 |
2015P000419 |
|
March 2016 |
June 2020 |
January 2021 |
March 31, 2017 |
June 4, 2018 |
|
- Beth Israel Deaconess Medial Center
Boston, Massachusetts, United States
|
|
| 15 |
NCT03487978 |
Enrolling by invitation |
Longitudinal Changes of Brain Functional Connectivity in Migraine |
|
- Diagnostic Test: resting-state functional MRI
|
Observational
|
|
- Samsung Medical Center
- National Research Foundation of Korea
- Sungkyunkwan University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Core fMRI features for migraine brain
- Candidate fMRI features for migraine
- Dynamic fMRI features for disease severity
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03487978 |
2017-03-113 |
|
July 24, 2017 |
April 30, 2018 |
February 28, 2020 |
April 4, 2018 |
April 20, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 16 |
NCT03152305 |
Recruiting |
Intracranial Pressure During Migraine |
|
- Other: Intracranial pressure variations
|
Observational
|
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Intracranial pressure variations
- Relationships between ICP variations and clinical parameters
- Relationships between ICP variations and pain relief
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT03152305 |
CHU-331
2014-A00042-45 |
MigICP |
July 21, 2014 |
May 2017 |
July 2018 |
May 15, 2017 |
May 15, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
|
| 17 |
NCT03004313 |
Completed |
Structural and Molecular Neuroplasticity in Migraine |
|
- Procedure: Pet Scan
- Procedure: MRI scan
- Procedure: Quantitative Sensory Testing (QST)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Level of mu-opioid receptor binding potential in the brain of episodic migraineurs during and outside the headache attack and compared to healthy controls.
- Correlation of migraine attack severity in migraineurs with mu-opioid receptor binding potential
|
32 |
All |
18 Years to 45 Years (Adult) |
NCT03004313 |
HUM00027383 |
|
January 2011 |
October 2014 |
October 2014 |
December 28, 2016 |
November 24, 2017 |
|
- University of Michigan - Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States
|
|
| 18 |
NCT01952574 |
Active, not recruiting
Has Results |
A Phase 2 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention |
|
- Drug: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change From Baseline in Monthly Migraine Days at Week 12
- Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12
- Change From Baseline in Monthly Migraine Attacks at Week 12
|
483 |
All |
18 Years to 60 Years (Adult) |
NCT01952574 |
20120178
2012-005331-90 |
|
August 6, 2013 |
September 25, 2014 |
November 11, 2019 |
September 30, 2013 |
September 3, 2018 |
July 10, 2018 |
- Research Site
Phoenix, Arizona, United States - Research Site
Long Beach, California, United States - Research Site
National City, California, United States - (and 63 more...)
|
|
| 19 |
NCT01687660 |
Unknown † |
Acupuncture for Migraine Prophylaxis |
- Migraine Without Aura
- Unilateral Headache
|
|
Interventional
|
Phase 2
Phase 3 |
- 973-2
- Hunan University of Traditional Chinese Medicine
- Chongqing Medical University
- Chengdu University of Traditional Chinese Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- frequency of migraine attacks
- headache severity
|
249 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01687660 |
2012CB518501-2 |
AMP |
September 2012 |
September 2014 |
September 2014 |
September 19, 2012 |
October 23, 2013 |
|
- Chengdu University of TCM
Chengdu, Sichuan, China
|
|
| 20 |
NCT02630459 |
Active, not recruiting |
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention |
|
- Drug: AMG 334 Dose Level 1
- Drug: Placebo
- Drug: AMG 334 Dose Level 2
- Drug: AMG 334 Dose Level 3
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean monthly migraine days
- Proportion of subjects with at least a 50% reduction from baseline in mean monthly migraine days
- Change from baseline in acute migraine-specific medication treatment days
|
475 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT02630459 |
20120309 |
|
January 6, 2016 |
September 25, 2017 |
June 3, 2019 |
December 15, 2015 |
December 6, 2017 |
|
- Research Site
Kamogawa-shi, Chiba, Japan - Research Site
Saijo-shi, Ehime, Japan - Research Site
Ota-shi, Gunma, Japan - (and 41 more...)
|
|
| 21 |
NCT01899040 |
Completed |
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache |
- Migraine Headache, Episodic
|
- Device: neuromodulation for episodic migraine headache
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of monthly migraine headache days
- Number of monthly migraine headache days (reduction by by 50% or more)
- Total monthly pain score
- (and 5 more...)
|
81 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01899040 |
SNS-MIG-01 |
|
August 2013 |
May 2016 |
June 2016 |
July 15, 2013 |
May 10, 2018 |
|
- Naval Medical Center
San Diego, California, United States - Michigan Headache and Neurological Institute
Ann Arbor, Michigan, United States - Carolina Headache Institute
Chapel Hill, North Carolina, United States - (and 3 more...)
|
|
| 22 |
NCT02108678 |
Completed |
One-Day Intervention for Depression and Impairment in Migraine Patients |
|
- Behavioral: ACT-ME
- Behavioral: Migraine Education Only
|
Interventional
|
Not Applicable |
- Baylor College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HRSD
- SCID-IV
- WHO-DAS-II
- (and 2 more...)
|
104 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02108678 |
201301712 |
ACT |
September 2013 |
September 2017 |
September 2017 |
April 9, 2014 |
December 22, 2017 |
|
- University of Iowa Carver College of Medicine Department of Psychiatry
Iowa City, Iowa, United States
|
|
| 23 |
NCT03521193 |
Recruiting |
Migraine Relief After Patent Foramen Ovale Closure: a Single Center Analysis |
- Platelet Aggregation, Spontaneous
- Migraine With Aura
- Patent Foramen Ovale
|
- Device: patent foramen ovale closure
|
Interventional
|
Not Applicable |
- Centro Cardiologico Monzino
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine and aura
- Platelet activation
- Platelet reactivity tests
- Clinical outcomes
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03521193 |
CCM769 |
|
February 15, 2018 |
December 30, 2019 |
June 30, 2020 |
May 10, 2018 |
May 10, 2018 |
|
- Centro Cardiologico Monzino, IRCCS
Milan, MI, Italy
|
|
| 24 |
NCT02945839 |
Not yet recruiting |
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department |
|
- Drug: Preventative Medication (PM)
- Behavioral: Enhanced Usual Care
- Behavioral: PMR (progressive muscle relaxation therapy)
|
Interventional
|
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline
- Perceived Stress Scale (PSS)
- Number of days/week treated with acute medications
- Number of drug administrations/week for acute medications
|
90 |
All |
18 Years to 64 Years (Adult) |
NCT02945839 |
16-00548 |
|
December 2018 |
December 2018 |
December 2018 |
October 26, 2016 |
May 31, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 25 |
NCT03453203 |
Not yet recruiting |
Treatment of Cervical Pain in Chronic Migraine |
|
- Other: Osteopathic Manipulative Treatment Using Counterstrain
|
Interventional
|
Not Applicable |
- University Hospitals Cleveland Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Treatment of Cervical Pain in Chronic Migraine
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03453203 |
UHClevelandMC1 |
|
April 29, 2018 |
December 29, 2018 |
December 29, 2018 |
March 5, 2018 |
March 7, 2018 |
|
|
|
| 26 |
NCT03190044 |
Recruiting |
Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis |
|
- Dietary Supplement: PACR
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of Roma La Sapienza
- Gianluca Coppola
- Francesco Pierelli
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Prevention
|
- Migraine improvement in terms of responder rate
- Migraine improvement in terms of frequencies
|
82 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03190044 |
ParMig Study |
ParMig |
June 6, 2017 |
November 30, 2017 |
December 31, 2017 |
June 16, 2017 |
June 16, 2017 |
|
- Policlinico Umberto I
Rome, Italy
|
|
| 27 |
NCT03217968 |
Completed
Has Results |
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device |
|
- Device: Cefaly® Abortive Program device
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Freedom (PF) at 2 Hours
- Most Bothersome Migraine-associated Symptom (MBS) Freedom at 2 Hours
- Pain Relief (PR) at 2 Hours
- (and 3 more...)
|
59 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03217968 |
50803 |
|
August 10, 2017 |
January 10, 2018 |
January 10, 2018 |
July 14, 2017 |
August 7, 2018 |
June 7, 2018 |
- Rochester Clinical Research, Inc.
Rochester, New York, United States
|
|
| 28 |
NCT03592329 |
Not yet recruiting |
Vagus Nerve Stimulation and Stress Reduction Training for Migraine |
|
- Behavioral: Stress Reduction Training A
- Device: active tVNS
- Behavioral: Stress Reduction Training B
- Device: sham tVNS
|
Interventional
|
Early Phase 1 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Brain activity changes in migraine patients in response to treatment
- Brain inflammation changes in migraine patients in response to treatment
- Brain activity differences between Migraine patients and healthy controls
- Brain inflammation differences between Migraine patients and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03592329 |
P01AT009965 |
|
February 2019 |
July 2023 |
July 2023 |
July 19, 2018 |
July 19, 2018 |
|
- Anthinoula A. Martinos Center
Charlestown, Massachusetts, United States
|
|
| 29 |
NCT01803984 |
Unknown † |
MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction |
|
- Device: MRI
- Device: EndoPAT
- Other: Neuropsychological battery
|
Observational
|
|
- University Hospital, Bordeaux
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Differences in magnetic resonance imaging (MRI) between migraine without aura and migraine with aura patients (frequency of hyperintensities, white matter lesions....)
- Differences in the Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between migraine without aura and migraine with aura patients.
- Differences in the Reactive Hyperemia Index (RHI) and the Augmentation Index (AI) between migraine without aura and migraine with aura patients
- Correlation between MRI and Total Score of RBANS with RHI / AI (endothelial function) between migraine groups.
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT01803984 |
CHUBX 2012/19 |
MIBRAIN |
March 2013 |
June 2015 |
June 2015 |
March 4, 2013 |
January 14, 2015 |
|
- Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
|
|
| 30 |
NCT01944059 |
Terminated
Has Results |
Theramine® in the Prevention of Migraine Headache |
|
- Drug: Theramine (medical food/old drug)
- Other: Placebo (l-alanine)
|
Interventional
|
Phase 4 |
- Vincent Martin, MD
- Targeted Medical Pharma
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Migraine/Headache Days
- Percent Change in Migraine and Headache Frequency
- HIT-6
|
31 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01944059 |
VM-2013-001 |
|
November 2013 |
December 2014 |
October 2015 |
September 17, 2013 |
May 5, 2016 |
May 4, 2016 |
- University Cincinnati Physicians Company
Cincinnati, Ohio, United States
|
|
| 31 |
NCT01720862 |
Completed |
Migraine and Body Composition |
- Migraine With and Without Aura
- Chronic Migraine
- Healthy Controls
|
|
Observational
|
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- association between migraine and obesity - evaluate serum adipokine levels
- association between migraine and obesity -evaluate subcutaneous adipose tissue (SAT) and its ratio to visceral adipose tissue (VAT)
|
300 |
Female |
18 Years to 50 Years (Adult) |
NCT01720862 |
NA_00051683 |
|
April 2012 |
October 2015 |
October 2015 |
November 2, 2012 |
January 28, 2016 |
|
- The Johns Hopkins Bayview Headache Center
Baltimore, Maryland, United States
|
|
| 32 |
NCT01653340 |
Completed |
A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine |
- Refractory Chronic Migraine
|
- Device: Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine
|
Interventional
|
Not Applicable |
- University of Roma La Sapienza
- Guy's and St Thomas' NHS Foundation Trust
- King's College Hospital NHS Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency in headache days
- Frequency in migraine days
- Frequency of moderate/severe headache days
- (and 8 more...)
|
18 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01653340 |
CE100112
2012-002005-22 |
rCM HF-SCS |
May 2012 |
February 2014 |
February 2014 |
July 31, 2012 |
February 19, 2014 |
|
- Sant'Andrea Hospital
Roma, RM, Italy
|
|
| 33 |
NCT02169830 |
Recruiting |
Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine |
|
- Drug: nortriptyline
- Drug: Topiramate
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- evaluate the comparative effectiveness of migraine diet, nortriptyline and topiramate
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02169830 |
24482_ Vest_Migraine |
|
June 2014 |
June 30, 2020 |
December 2020 |
June 23, 2014 |
September 6, 2018 |
|
- Saint Louis University
Saint Louis, Missouri, United States
|
|
| 34 |
NCT03108469 |
Active, not recruiting |
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine |
|
- Drug: IONIS-PKKRx (ISIS 546254)
- Other: Placebo
|
Interventional
|
Phase 2 |
- Smith, Timothy R., M.D.
- Clinvest Research, LLC
- Ionis Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Comparison of Adverse Events
- Change in Migraine Days
- Change in Headache Severity
- (and 6 more...)
|
43 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03108469 |
15-001IS |
|
August 1, 2017 |
December 31, 2018 |
December 31, 2018 |
April 11, 2017 |
September 5, 2018 |
|
- StudyMetrix
Saint Peters, Missouri, United States - Clinvest Research, LLC
Springfield, Missouri, United States
|
|
| 35 |
NCT03238781 |
Active, not recruiting |
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention |
- Chronic Migraine or Episodic Migraine
|
- Drug: Placebo
- Drug: AMG 301
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from the baseline period in monthly migraine days. The monthly migraine days will be calculated using the migraine days over the last 4 weeks of the 12-week double-blind treatment period.
- At least a 50% reduction from the baseline period in monthly migraine days in the last 4 weeks of the 12-week double-blind treatment period
- Change from the baseline period in monthly acute migraine-specific medication days in the last 4 weeks of the 12-week double-blind treatment period.
- (and 2 more...)
|
343 |
All |
18 Years to 60 Years (Adult) |
NCT03238781 |
20150308
2017-000630-57 |
|
September 6, 2017 |
October 16, 2018 |
February 4, 2019 |
August 3, 2017 |
August 10, 2018 |
|
- Research Site
Long Beach, California, United States - Research Site
Santa Monica, California, United States - Research Site
Boulder, Colorado, United States - (and 46 more...)
|
|
| 36 |
NCT02456740 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention |
|
- Drug: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period
- Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days in the Last 3 Months of the Double-blind Treatment Phase
- Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days to the Last 3 Months of the Double-blind Treatment Period
- (and 2 more...)
|
955 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02456740 |
20120296
2014-004464-38 |
STRIVE |
July 17, 2015 |
September 5, 2016 |
June 19, 2017 |
May 28, 2015 |
July 10, 2018 |
July 10, 2018 |
- Research Site
Phoenix, Arizona, United States - Research Site
Anaheim, California, United States - Research Site
Encino, California, United States - (and 126 more...)
|
|
| 37 |
NCT01687101 |
Completed
Has Results |
STOPAIN in the Treatment of a Single Migraine Attack |
|
- Drug: STOPAIN topical gel
|
Interventional
|
Not Applicable |
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of STOPAIN in the Acute Treatment of Migraine
|
32 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01687101 |
SDS/STPAIN/01 |
|
May 2012 |
May 2013 |
May 2013 |
September 18, 2012 |
June 9, 2017 |
April 27, 2015 |
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 38 |
NCT01476930 |
Completed |
Cupping and Serkangabin Versus Conventional Migraine Treatment |
|
- Procedure: cupping and serkangabin syrup
- Drug: conventional migraine drug treatment
|
Interventional
|
Phase 4 |
- Birjand University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- frequency of migraine attacks per week
- severity of migraine attacks
- duration of migraine attacks
- frequency of migraine attacks
|
391 |
All |
15 Years to 50 Years (Child, Adult) |
NCT01476930 |
n231
n231hej |
|
June 2008 |
September 2009 |
October 2011 |
November 22, 2011 |
November 24, 2014 |
|
- Birjand University of Medical Sciences,Valiasr Hospital
Birjand, South Khorasan, Iran, Islamic Republic of
|
|
| 39 |
NCT00904150 |
Completed
Has Results |
Study of the Molecular Genetics of Menstrual Migraine |
|
|
Observational
|
|
- The City of London Migraine Clinic
- Griffith University
- The City of London Migraine Clinic
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Progesterone Receptor Gene Polymorphism PROGINS in Women With Menstrual Migraine and Women Without Migraine
- Estrogen Receptor 1 G594a Polymorphism in Women With Menstrual Migraine and Women Without Migraine
- Estrogen Receptor 1 C325G Polymorphism in Women With Menstrual Migraine and Women Without Migraine
- (and 4 more...)
|
585 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00904150 |
COLMC-GEN-2007
REC Ref: 07/H0703/107
Proposal # 36470
Grant Application 2007/03 |
|
November 2007 |
August 2013 |
August 2013 |
May 19, 2009 |
February 24, 2014 |
February 24, 2014 |
- The City of London Migraine Clinic
London, United Kingdom
|
|
| 40 |
NCT03651583 |
Completed
New |
Examining the Efficacy of Kiko Exercises on the Prevention of Migraine Headaches |
|
- Behavioral: Kiko exercises-combines breathing and movement
|
Interventional
|
Early Phase 1 |
- Regional Clinical Research
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in Migraine Frequency and Severity from Baseline
- Change in number of headache free days
- Change in number of migraine free days
- (and 2 more...)
|
13 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03651583 |
Kiko Protocol 01 |
|
January 2006 |
May 2006 |
May 2006 |
August 29, 2018 |
August 29, 2018 |
|
- Endwell Family Physicians
Endwell, New York, United States
|
|
| 41 |
NCT02562196 |
Unknown † |
tDCS for the Treatment of Migraine |
|
|
Interventional
|
Phase 2 |
- Universidade Federal de Pernambuco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in headache diary variables
- Changes on Visual Evoked Potentials measures
- Changes on HIT-6
- (and 5 more...)
|
14 |
All |
18 Years to 55 Years (Adult) |
NCT02562196 |
Effect_tDCS_Migraine |
|
March 2016 |
August 2016 |
April 2018 |
September 29, 2015 |
May 11, 2016 |
|
- Applied Neuroscience Laboratory
Recife, Pernambuco, Brazil
|
|
| 42 |
NCT02066415 |
Completed
Has Results |
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention |
- Treatment for Prevention of Chronic Migraine
|
- Biological: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change From Baseline in Monthly Migraine Days
- Percentage of Participants With at Least a 50% Reduction in Monthly Migraine Days From Baseline
- Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days
- (and 3 more...)
|
667 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02066415 |
20120295
2013-001707-36 |
|
March 5, 2014 |
February 24, 2016 |
April 28, 2016 |
February 19, 2014 |
June 21, 2018 |
June 21, 2018 |
- Research Site
La Jolla, California, United States - Research Site
Newport Beach, California, United States - Research Site
San Francisco, California, United States - (and 71 more...)
|
|
| 43 |
NCT03465904 |
Active, not recruiting |
A Phase III Trial of e-TNS for the Acute Treatment of Migraine |
|
- Device: Verum Cefaly® Abortive Program device
- Device: Sham Cefaly® Abortive Program device
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain Freedom at 2 hours
- Most bothersome migraine-associated symptom freedom at 2 hours
- Pain Relief at 2 hours
- (and 4 more...)
|
600 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03465904 |
51401 |
TEAM |
April 10, 2018 |
October 2018 |
October 2018 |
March 14, 2018 |
September 26, 2018 |
|
- Clinical Research Consortium
Tempe, Arizona, United States - Pharmacology Research Institute
Encino, California, United States - Yale University
New Haven, Connecticut, United States - (and 7 more...)
|
|
| 44 |
NCT01924052 |
Completed |
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
|
- CGRP induced migraine attacks in patients with high and low genetic load
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01924052 |
H-2-2011-141 |
|
June 2013 |
August 2013 |
August 2013 |
August 16, 2013 |
August 16, 2013 |
|
|
|
| 45 |
NCT02593097 |
Recruiting |
Metformin for the Prevention of Episodic Migraine (MPEM) |
|
- Drug: Metformin
- Drug: Matching Placebo
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The reduction in the number of migraine days per month during 12 weeks of treatment with metformin vs placebo (primary end point).
- The response rate (percentage of patients with a >50% reduction in migraine days per month) during 12 weeks of treatment with metformin vs placebo (secondary end point).
- Number of participants with treatment-related adverse events
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02593097 |
15-000422 |
MPEM |
February 2016 |
December 2017 |
December 2018 |
October 30, 2015 |
October 30, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
|
|
| 46 |
NCT03459495 |
Not yet recruiting |
Therapeutic Ultrasound in the Treatment of Migraine |
|
- Device: therapeutic ultrasound
- Device: placebo ultrasound
|
Interventional
|
Not Applicable |
- Bursa Yüksek İhtisas Education and Research Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Numeric rating scale (NRS)
- Migraine Disability Assessment Questionnaire Score (MIDAS)
- paracetamol consumption
- the number of migraine attacks per month.
|
58 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03459495 |
2011-KAEK-2018-1/25 |
|
March 10, 2018 |
September 10, 2018 |
September 10, 2018 |
March 9, 2018 |
March 9, 2018 |
|
|
|
| 47 |
NCT02616978 |
Completed |
Retrospective Study on the Use of CEFALY® Device During Migraine Attacks |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Monthly number of acute drug intake avoided when using Cefaly to treat a migraine attack
- Proportion of Cefaly users that report using also the device to treat migraine attacks
- Proportion of migraine attacks treated with the Cefaly device
- Proportion of migraine attacks for which the use of the Cefaly device generate a reduction of drug intake
|
807 |
All |
Child, Adult, Older Adult |
NCT02616978 |
50214 |
|
November 2015 |
December 2015 |
December 2015 |
November 30, 2015 |
May 8, 2017 |
|
|
|
| 48 |
NCT03414203 |
Recruiting |
Comparison Between Transcranial Stimulation Protocols With Continuous Current in the Chronic Migraine |
|
|
Interventional
|
Not Applicable |
- Federal University of Paraíba
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment - MIDAS
- Headache Impact Test - HIT-6
- Wechsler Intelligence Scale Letters
- (and 10 more...)
|
45 |
Female |
20 Years to 45 Years (Adult) |
NCT03414203 |
NEUROMIG |
NEUROMIG |
August 14, 2017 |
February 5, 2018 |
April 16, 2018 |
January 29, 2018 |
January 29, 2018 |
|
- Federal University of Paraiba
João Pessoa, Paraiba, Brazil
|
|
| 49 |
NCT03337620 |
Recruiting |
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine |
|
|
Interventional
|
Phase 3 |
- Tian Medical Inc.
- TAMM Net, Inc.
- Clinvest Research, LLC
- New England Institute for Clinical Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Migraine Headaches During Treatment Phase
- Change in Number of Migraine Headache Days Post-Treatment
- Safety/Tolerability of TX360 Device Based on Adverse Effects
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03337620 |
16-001TI |
|
September 20, 2017 |
January 1, 2019 |
June 1, 2019 |
November 9, 2017 |
March 5, 2018 |
|
- Hartford Headache Center
East Hartford, Connecticut, United States - Waterbury Neurology
Middlebury, Connecticut, United States - Yale University
New Haven, Connecticut, United States - (and 5 more...)
|
|
| 50 |
NCT02765581 |
Recruiting |
Efficacy Study of Acupuncture in the Prevention of Migraine Without Aura |
|
- Device: Verum acupuncture
- Device: Sham acupuncture
- Behavioral: Usual care
|
Interventional
|
Not Applicable |
- Wei Wang
- Hubei College of Traditional Chinese Medicine
- Hubei Hospital of Traditional Chinese Medicine
- (and 6 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the number of migraine days
- Change in the frequency of migraine attacks
- The proportion of responders
- (and 7 more...)
|
150 |
All |
15 Years to 65 Years (Child, Adult, Older Adult) |
NCT02765581 |
201403RCTMWA |
|
May 1, 2016 |
December 31, 2018 |
June 30, 2019 |
May 6, 2016 |
June 1, 2018 |
|
- Department of Neurology of Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
|
| 51 |
NCT01197196 |
Unknown † |
Behavioral Weight Loss as a Treatment for Migraine in Obese Women |
|
- Behavioral: Behavioral Weight Loss Intervention
- Other: Migraine Education
|
Interventional
|
Not Applicable |
- The Miriam Hospital
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the number of migraine headache days
- Change in body weight
- Changes in serum inflammatory markers (C-reactive protein, Interleukin-6)
- (and 3 more...)
|
112 |
Female |
18 Years to 50 Years (Adult) |
NCT01197196 |
0068-10
R01NS077925-01A1 |
|
July 2012 |
June 2017 |
June 2017 |
September 9, 2010 |
December 21, 2016 |
|
- The Miriam Hospital Weight Control and Diabetes Research Center
Providence, Rhode Island, United States
|
|
| 52 |
NCT02748577 |
Recruiting |
Pain Processing in Adults With Migraines |
|
- Other: Questionnaires
- Other: Quantitative Sensory Testing (QST) Pain Measurements
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Heat Pain Intensity coefficient and intercept from stimulus response curve
- Heat Pain Unpleasantness coefficient and intercept from stimulus response curve
- Pain Catastophizing score
- (and 13 more...)
|
98 |
All |
18 Years and older (Adult, Older Adult) |
NCT02748577 |
IRB00027845 |
|
January 2016 |
July 2020 |
July 2020 |
April 22, 2016 |
July 16, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 53 |
NCT02122744 |
Completed |
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine |
|
- Device: Super Rapid Magstim Stimulator
|
Interventional
|
Phase 3 |
- University Hospital of Liege
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Frequency of migraine
- Intensity of migraine
- Acute medication intake
- (and 2 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02122744 |
CB-1331 |
|
September 2013 |
April 2014 |
September 2014 |
April 25, 2014 |
May 28, 2015 |
|
- Roberta Baschi
Liège, Belgium
|
|
| 54 |
NCT03175263 |
Completed |
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain |
|
|
Observational
|
|
- University Hospital, Limoges
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- frequency of headache days
- the proportion of patients with a ≥ 70% decrease in headache day frequency
- the decrease in triptan consumption
- the assessment of patient satisfaction
|
57 |
All |
18 Years and older (Adult, Older Adult) |
NCT03175263 |
I17022 |
|
September 1, 2008 |
December 30, 2015 |
December 30, 2015 |
June 5, 2017 |
June 5, 2017 |
|
|
|
| 55 |
NCT02686034 |
Recruiting |
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks |
|
- Device: gammaCore-S
- Device: gammaCore-S Sham
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment Response - No Pain
- Nausea/Vomiting
- Treatment Response - No Pain or Mild Pain
- Sustained Treatment Response
|
300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02686034 |
GM-16 |
|
January 2016 |
December 2016 |
April 2017 |
February 19, 2016 |
November 28, 2016 |
|
- University Aldo Moro, Ospedale Pediatrico
Bari, Italy - IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria
Bologna, Italy - University Hospital of Careggi
Florence, Italy - (and 7 more...)
|
|
| 56 |
NCT01010711 |
Unknown † |
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents |
|
- Dietary Supplement: Migra 3
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of days with headache before and after 12 weeks of daily treatment with a migraine specific dietary supplement
- frequency, duration and intensity of the migraine
|
76 |
All |
8 Years to 17 Years (Child) |
NCT01010711 |
TOM-DS-CH-1 |
|
November 2009 |
December 2010 |
April 2011 |
November 10, 2009 |
February 2, 2010 |
|
- Universiätsklinikum Essen Neurologische Klinik, Westdeutsches Kopfschmerzzentrum, Hufelandstr.26,
Essen, Nordrhein-Westfalen, Germany - Migräne und Kopfschmerzklinik Königstein
Königstein Im Taunus, Germany
|
|
| 57 |
NCT03333109 |
Recruiting |
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients |
|
- Biological: Erenumab
- Other: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from baseline in monthly migraine days at the last month (Month 3) of the double-blind treatment period (DBTP)
- Achievement of at least a 50% reduction from baseline in monthly migraine days at Month 3
- Change from Baseline in acute migraine-specific medication treatment days at Month 3
- Change from Baseline in headache impact scores as measured by the HIT-6 at Month 3
|
880 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03333109 |
CAMG334A2302 |
EMPOwER |
February 8, 2018 |
February 7, 2020 |
February 7, 2020 |
November 6, 2017 |
September 18, 2018 |
|
- Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Buenos Aires, Argentina - (and 61 more...)
|
|
| 58 |
NCT02969642 |
Recruiting |
Study of Low-level Laser Therapy in the Acute Treatment of Migraine |
|
- Device: Argus Migraine Treatment device
|
Interventional
|
Phase 2 |
- The San Francisco Clinical Research Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Differences between treatment groups in pain free rates at 2 hours post treatment.
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02969642 |
AP 1001 |
|
March 2016 |
May 2017 |
July 2017 |
November 21, 2016 |
December 2, 2016 |
|
- San Francisco Clinical Research Center
San Francisco, California, United States
|
|
| 59 |
NCT01916395 |
Completed |
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache |
|
- Drug: sumatriptan and Treximet
|
Observational
|
|
- Gary E. Ruoff, M.D.
- GlaxoSmithKline
- Westside Family Medical Center, P.C.
|
Other / Industry |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- The outcome will be to determine whether inflammatory markers are reduced in patients having a migraine when treated with Imitrex 100mg or Treximet.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01916395 |
GR10 |
|
December 2009 |
December 2010 |
July 2011 |
August 5, 2013 |
August 5, 2013 |
|
- Westside Family Medical Center, PC
Kalamazoo, Michigan, United States
|
|
| 60 |
NCT02021474 |
Unknown † |
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis |
|
- Drug: Histamine Dihydrochloride
- Drug: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mean change from baseline in monthly migraine days [time frame: baseline and average over Weeks 3-22].
- Mean change from baseline in monthly migraine days by 4 week intervals [Weeks 3-6, 7-10, 11-14, 15-18, 19-22].
- Mean Change from Baseline in Monthly Migraine Index (MMI)
- Mean change from baseline in monthly number of migraines
|
130 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02021474 |
HSC-201 |
|
September 2015 |
September 2016 |
|
December 27, 2013 |
January 27, 2015 |
|
|
|
| 61 |
NCT01820559 |
Completed
Has Results |
Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine |
|
- Drug: Placebo
- Drug: ESL 1200 mg
- Drug: ESL 800 mg
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Absolute Change From Baseline in the Frequency of Migraine Attacks
|
452 |
All |
18 Years and older (Adult, Older Adult) |
NCT01820559 |
BIA-2093-209 |
|
April 2009 |
June 2010 |
June 2010 |
March 29, 2013 |
May 24, 2013 |
May 24, 2013 |
|
|
| 62 |
NCT02483585 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention |
|
- Drug: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Monthly Migraine Days at Week 12
- Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12
- Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days at Week 12
- (and 4 more...)
|
577 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02483585 |
20120297
2014-004463-20 |
ARISE |
July 19, 2015 |
July 11, 2016 |
March 20, 2017 |
June 29, 2015 |
August 8, 2018 |
June 25, 2018 |
- Research Site
Birmingham, Alabama, United States - Research Site
Phoenix, Arizona, United States - Research Site
Culver City, California, United States - (and 73 more...)
|
|
| 63 |
NCT02315833 |
Recruiting |
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients |
|
- Drug: Acetium
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Biohit Oyj
- The Finnish Funding Agency for Technology and Innovation (TEKES)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of migraine attacks (NMA) per evaluation interval
- Number of migraine days (NMD) per evaluation period
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02315833 |
AC-MIGPREV-1 |
|
June 2014 |
February 2019 |
February 2019 |
December 12, 2014 |
September 24, 2018 |
|
- Confido Privat Medical Clinic
Tallinn, Estonia - Tartu University Hospital, Neurology Clinic
Tartu, Estonia - Terveystalo, Kamppi
Helsinki, Finland - (and 4 more...)
|
|
| 64 |
NCT00910689 |
Completed
Has Results |
Drug and Non-Drug Treatment Of Severe Migraine |
|
- Drug: Propranolol or nadolol
- Drug: Placebo control
- Behavioral: Behavioral Migraine Management (BMM)
- Drug: Optimal Acute Therapy
|
Interventional
|
Phase 4 |
- Ohio University
- National Institute of Neurological Disorders and Stroke (NINDS)
- Merck Sharp & Dohme Corp.
- GlaxoSmithKline
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Migraine Episodes Per 30 Days at Month 10.
- Change in the Number of Migraine Days Per 30 Days at Month 10
- Change in Quality of Life at Month 10
- (and 3 more...)
|
232 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00910689 |
2R01NS032374
NS32374 |
TSM |
July 2001 |
November 2005 |
November 2005 |
June 1, 2009 |
November 22, 2016 |
June 1, 2009 |
- Ohio University
Athens, Ohio, United States - OrthoNeuro, Inc.
Westerville, Ohio, United States
|
|
| 65 |
NCT02468622 |
Completed |
Transcriptomic and Biochemical Changes During a Migraine Attack |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Transcriptomic changes
- Changes in CGRP levels during a migraine attack (CGRP1-37, CGRP1-17, CGRP18-37, CGRP1-26, CGRP27-37)
- Changes in PACAP levels during a migraine attack (PACAP-27, PACAP-38 )
- Changes in VIP, glutamate, serotonin, PGE-2, nitric oxide metabolites, cAMP, and cGMP
|
30 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02468622 |
Transcriptomics |
|
August 2015 |
June 2016 |
June 2016 |
June 11, 2015 |
May 9, 2017 |
|
- Emma Katrine Hansen
Copenhagen, Glostrup, Denmark
|
|
| 66 |
NCT02592681 |
Unknown † |
Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine |
|
- Procedure: verum acupuncture
- Procedure: acupressure
- Procedure: control acupuncture
|
Interventional
|
Not Applicable |
- Western University, Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- change from baseline menstrual migraine attack frequency at 9 months
- change from baseline number of migraine days at 9 months
- change from baseline average visual analogue scale (VAS) at 9 months
- (and 3 more...)
|
120 |
Female |
18 Years to 40 Years (Adult) |
NCT02592681 |
WesternUCanada-acu |
|
November 2015 |
August 2016 |
August 2016 |
October 30, 2015 |
October 30, 2015 |
|
|
|
| 67 |
NCT02309606 |
Completed |
Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography |
|
- Other: PET scan with 5-HT receptor ligands
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Differences in binding of the 5-HT1B radioligand
- Differences in binding of the 5-HT4 radioligand
- Correlation with migraine frequency and 5-HT4 receptor binding
|
56 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02309606 |
H-6-2014-057 |
|
January 2015 |
August 2017 |
December 2017 |
December 5, 2014 |
January 31, 2018 |
|
- Danish Headache Center, Glostrup Hospital
Glostrup, Copenhagen, Denmark
|
|
| 68 |
NCT01004835 |
Completed |
The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS) |
|
|
Observational
|
|
- Scripps Translational Science Institute
|
Other |
- Observational Model: Family-Based
|
|
61 |
All |
10 Years and older (Child, Adult, Older Adult) |
NCT01004835 |
HSC# 08-5099 |
MAPS |
January 2009 |
May 2015 |
May 2015 |
October 30, 2009 |
October 16, 2015 |
|
- Scrippshealth
La Jolla, California, United States
|
|
| 69 |
NCT01060111 |
Completed
Has Results |
An Efficacy and Tolerability Study of Topiramate in Participants With Migraine |
|
- Drug: Topiramate Standard
- Drug: Topiramate Slow
- Drug: Propranolol booster
|
Interventional
|
Phase 4 |
- Janssen Korea, Ltd., Korea
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Percentage Decrease in Migraine Episodes
- Change From Baseline in Migraine Frequency at Week 6
- Change From Baseline in Migraine Disability Assessment (MIDAS) Score at Week 6
- Change From Baseline in Visual Analogue Scale (VAS) Score at Week 6
|
250 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01060111 |
CR011944
MIG-KOR-001 |
|
July 2006 |
July 2008 |
July 2008 |
February 2, 2010 |
August 22, 2013 |
August 6, 2013 |
- Busan, Korea, Republic of
- Daegu, Korea, Republic of
- Kwangjoo, Korea, Republic of
- (and 3 more...)
|
|
| 70 |
NCT02188394 |
Completed |
Anesthetic Blockades and Migraine |
|
- Drug: Anesthetic blockades with bupivacaine
- Drug: Isotonic saline injection
|
Interventional
|
Phase 2 |
- César Fernández-de-las-Peñas
- Universidad Rey Juan Carlos
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in the number of days with moderate/intense migraine
- Changes in the number of days with mild/moderate migraine
- Changes in the number of symptomatic medication drugs
- Changes in pressure pain thresholds
|
36 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT02188394 |
HCSC11/263 |
|
July 2014 |
January 2016 |
January 2016 |
July 11, 2014 |
January 5, 2016 |
|
- Hospital Universitario Clinico San Carlos-Universidad Complutense de Madrid
Madrid, Spain
|
|
| 71 |
NCT02580968 |
Completed |
Study of Key Electro-acupuncture Technique on Migraine |
|
- Device: electro-acupuncture
- Drug: flunarizine hydrochloride
|
Interventional
|
Not Applicable |
- Shanghai University of Traditional Chinese Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Questionnaire (MIDAS)
- The medical outcomes study 36-item short-form health survey(SF-36)
- peripheral Nitrogen Monoxide(NO) protein expression
- (and 3 more...)
|
2 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02580968 |
643857003534 |
|
March 2015 |
December 2017 |
December 2017 |
October 20, 2015 |
March 29, 2018 |
|
- Longhua Hospital,Shanghai University of Traditional Chinese Medicine
Shanghai, China
|
|
| 72 |
NCT03559257 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days in Participants with Episodic Migraine
- Percentage of Participants with ≥50% Reduction from Baseline in Monthly Migraine Headache Days
- (and 10 more...)
|
420 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03559257 |
16670
I5Q-MC-CGAW
2018-000600-42 |
CONQUER |
July 31, 2018 |
July 10, 2019 |
October 31, 2019 |
June 18, 2018 |
September 20, 2018 |
|
- 21st Century Neurology
Phoenix, Arizona, United States - Medical Center for Clinical Research
San Diego, California, United States - California Medical Clinic for Headache
Santa Monica, California, United States - (and 77 more...)
|
|
| 73 |
NCT02708797 |
Completed |
Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura. |
|
- Other: Magnetic resonance imaging
- Other: Transcranial Doppler
|
Interventional
|
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Correlation between the density of the pontine grey matter evaluated with resonance magnetic imaging, and cerebral autoregulation measured with Transcranial Doppler in migraine with aura patients and controls.
- Comparison of brainstem grey matter density between migraine with aura patients and controls with magnetic resonance imaging
- Comparison of cerebral autoregulation between migraine with aura patients and controls with Transcranial Doppler
- (and 6 more...)
|
46 |
All |
30 Years to 55 Years (Adult) |
NCT02708797 |
RC31/15/7815
2015-A01982-47 |
MINOTAURE |
May 2016 |
April 2017 |
April 2017 |
March 15, 2016 |
February 6, 2018 |
|
- CHU Toulouse
Toulouse, France
|
|
| 74 |
NCT01617941 |
Withdrawn |
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention |
- Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
|
- Drug: BGG492
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Frequency of migraine attacks
- Number of migraine attacks
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT01617941 |
CBGG492A2214
2011-005316-28 |
|
May 2016 |
November 2016 |
November 2016 |
June 13, 2012 |
April 20, 2017 |
|
|
|
| 75 |
NCT02795351 |
Recruiting |
Induction of Migraine Aura With Sildenafil |
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aura and migraine like headache
- Markers of endothelial function in blood
- Migraine without aura
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT02795351 |
H-15008491 |
|
June 2015 |
June 2018 |
August 2018 |
June 10, 2016 |
March 22, 2018 |
|
- Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
|
|
| 76 |
NCT02784847 |
Unknown † |
A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine |
|
|
Interventional
|
Early Phase 1 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in monthly migraine days
- Change in mean attack severity
- Change in mean attack duration
- Number of patients who have at least a 50% reduction in monthly migraine days
|
10 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT02784847 |
UX007 |
TRIMI |
June 2016 |
November 2016 |
November 2016 |
May 27, 2016 |
May 27, 2016 |
|
|
|
| 77 |
NCT03194555 |
Active, not recruiting |
Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in Episodic Migraine Prevention (ANODYNE-3) |
- Migraine With or Without Aura
|
- Drug: ALLOD-2 Capsules
- Drug: Placebo Capsules
|
Interventional
|
Phase 2
Phase 3 |
- Allodynic Therapeutics, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in the mean number of migraine/probable migraine headache days.
- Change from baseline in the mean number of headache days.
- Proportion of patients with 50% or more reduction in migraine/probable migraine headache days.
- (and 9 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT03194555 |
ANODYNE-3 |
|
August 1, 2017 |
August 2018 |
October 2018 |
June 21, 2017 |
April 17, 2018 |
|
- Annette Toledano, M.D.
North Miami, Florida, United States
|
|
| 78 |
NCT00893737 |
Completed
Has Results |
"Completeness of Response" Following Treatment With Treximet™ for Migraine |
|
- Drug: sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
|
Interventional
|
Phase 4 |
- Cady, Roger, M.D.
- GlaxoSmithKline
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Scores From Completeness of Response Survey (CORS)
- Percent of Participants Reporting Treximet Provides Therapeutic Advantage Over Usual Pre-study Triptan
- Paired T-test Indicating Greater Subject Satisfaction With Treximet Over Usual Pre-study Triptan as Determined by the Revised Patient Perception of Migraine Questionnaire (PPMQ-R)
|
147 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00893737 |
110211 |
|
June 2009 |
January 2010 |
January 2010 |
May 6, 2009 |
January 25, 2011 |
January 25, 2011 |
- San Francisco Clinical Research Center
San Francisco, California, United States - Westside Family Medical Center
Kalamazoo, Michigan, United States - Clinvest
Springfield, Missouri, United States - (and 5 more...)
|
|
| 79 |
NCT01629329 |
Terminated |
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine |
|
- Drug: Aspirin, Acetaminophen, Caffeine pills
- Drug: Prochlorperazine 10mg
|
Interventional
|
Phase 4 |
- Albert Einstein Healthcare Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Mean difference from baseline of VAS pain scores
- Number of reported adverse side-effects
|
93 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01629329 |
4258 |
Migraine |
November 2010 |
April 2014 |
April 2014 |
June 27, 2012 |
June 25, 2014 |
|
- Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
|
|
| 80 |
NCT01695460 |
Completed |
A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine |
- Migraine According to International Headache Society (IHS) Criteria (ICHD-II)
|
- Drug: D3 Vitamin ®
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Aalborg University
- CCBR Aalborg A/S, Aalborg, Denmark
- Aalborg Universitetshospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- The number of migraine attacks
- Evaluation of pain during migraine attacks
- Hypersensitivity
- (and 3 more...)
|
48 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01695460 |
N-20120052
Projekt #831302 |
|
September 2012 |
December 2015 |
December 2015 |
September 28, 2012 |
December 29, 2015 |
|
- CCBR Aalborg A/S
Aalborg, Denmark - Aalborg University
Aalborg, Denmark
|
|
| 81 |
NCT03022838 |
Recruiting |
The Effects of Caffeine Withdrawal on Migraine |
- Migraine
- Caffeine Withdrawal
|
|
Interventional
|
Phase 2
Phase 3 |
- Nordlandssykehuset HF
- King's College London
- University Hospital of North Norway
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine days
- Withdrawal symptoms and/or syndrome (according to criteria)
- Migraine attacks
- (and 2 more...)
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03022838 |
2015/1729REK |
|
February 28, 2017 |
February 28, 2019 |
November 2019 |
January 18, 2017 |
December 29, 2017 |
|
- Nordland Hospital
Bodø, Norway - Departement of Neurology, NLSH HF
Bodø, Norway - Departement of Neurology
Tromsø, Norway
|
|
| 82 |
NCT02991430 |
Terminated |
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache |
|
- Device: active neuromodulation for episodic migraine headache
- Device: placebo neuromodulation for episodic migraine headache
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- change in migraine headache days (MHD)
- normalized reduction in migraine headache days
- change in medication usage
- (and 7 more...)
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02991430 |
SNS-MIG-02 |
|
June 30, 2017 |
May 11, 2018 |
May 11, 2018 |
December 13, 2016 |
May 17, 2018 |
|
- Mayo Clinic
Scottsdale, Arizona, United States - Neurology Research Institute
West Palm Beach, Florida, United States - Diamond Headache Clinic
Chicago, Illinois, United States - (and 7 more...)
|
|
| 83 |
NCT03536936 |
Completed |
Oxygenation and Perfusion in Patients With Acute Migraine Attacks |
- Migraine
- Migraine With Aura
- Migraine; Status
|
|
Observational
|
|
- University Hospital Inselspital, Berne
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Focal cerebral hypoperfusion and elevated oxygenation in acute migraine attack
|
1000 |
All |
6 Years to 80 Years (Child, Adult, Older Adult) |
NCT03536936 |
Migraine Brain Perfusion |
OPAMA |
January 1, 2010 |
April 30, 2018 |
April 30, 2018 |
May 25, 2018 |
May 25, 2018 |
|
|
|
| 84 |
NCT02307071 |
Unknown † |
Occipital Transcutaneous Stimulation in Chronic Migraine |
|
- Device: Cefaly Kit Arnold
|
Interventional
|
Phase 4 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Monthly frequency of migraine days
- Monthly frequency of headache days
- Monthly frequency of total headache days
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02307071 |
OTSCM |
OSCRO |
November 2014 |
September 2015 |
December 2015 |
December 3, 2014 |
May 28, 2015 |
|
- CHR Citadelle
Liege, Belgium
|
|
| 85 |
NCT00846495 |
Completed
Has Results |
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine |
|
- Drug: topiramate
- Drug: frovatriptan
|
Interventional
|
Phase 4 |
- Clinvest
- Endo Pharmaceuticals
- Cady, Roger, M.D.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate
- Number of Headache Days Reported by Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate to Prevent Migraine
- Number of Headache Days Each Month Following Initiation of Treatment With Study Medication
- (and 5 more...)
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT00846495 |
Frova vs. Topiramate |
|
August 2009 |
January 2011 |
January 2011 |
February 18, 2009 |
January 13, 2012 |
August 9, 2011 |
- Physician Associates LLC
Oviedo, Florida, United States - Clinvest
Springfield, Missouri, United States
|
|
| 86 |
NCT02158221 |
Completed |
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
|
- Incidence of migraine attacks induced by PACAP in patients with high and low genetic load.
- Incidence of headache induced by PACAP in patients with high and low genetic load.
|
32 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02158221 |
H-2-2013-043 |
|
June 2014 |
November 2014 |
December 2014 |
June 6, 2014 |
February 10, 2015 |
|
- Danish Headache Center & Department of Neurology
Copenhagen, Glostrup, Denmark
|
|
| 87 |
NCT01723514 |
Completed |
Ascending Multiple-Doses of AMG 334 in Healthy Subjects and in Migraine Patients |
|
- Drug: AMG 334
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs.
- The maximum observed concentration, time to maximum concentration and the area under the serum-concentration curve after multiple doses of AMG 334.
- The ratio of blood flow measure at 30 minute post capsaicin challenge to the flow measure prior to the capsaicin challenge.
|
48 |
All |
18 Years to 55 Years (Adult) |
NCT01723514 |
20101268 |
|
November 2012 |
July 2014 |
July 2014 |
November 8, 2012 |
July 28, 2014 |
|
- Research Site
Leuven, Belgium
|
|
| 88 |
NCT02686983 |
Unknown † |
GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study |
|
- Drug: Betamethasone and local anesthetic
|
Interventional
|
Phase 4 |
- Jakob Møller Hansen, MD.
- Danish Headache Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of migraine days
- Number of days with severe headache days
- Medication use
- (and 2 more...)
|
34 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02686983 |
DHC-GON-1 |
DHC-GON-1 |
March 2016 |
March 2018 |
July 2018 |
February 22, 2016 |
February 23, 2016 |
|
- Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital
Glostrup, Copenhagen, Denmark
|
|
| 89 |
NCT03432286 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the Number of Monthly Migraine Headache Days
- Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days
- Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting
- (and 13 more...)
|
224 |
All |
6 Years to 17 Years (Child) |
NCT03432286 |
16352
I5Q-MC-CGAS
2017-004351-23 |
REBUILD |
March 14, 2018 |
March 21, 2022 |
April 10, 2023 |
February 14, 2018 |
September 19, 2018 |
|
- Medical Center for Clinical Research
San Diego, California, United States - Clinical Neuroscience Solutions Inc
Jacksonville, Florida, United States - Sensible Healthcare
Ocoee, Florida, United States - (and 14 more...)
|
|
| 90 |
NCT01688739 |
Completed |
Ascending Single Doses of AMG 334 in Healthy Subjects and Migraine Patients |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs.
- The number of subjects with anti-AMG 334 antibodies after a single dose of AMG 334.
- The maximum observed concentration, time to maximum concentration and the area under the serum-concentration curve after a single dose of AMG 334.
- The ratio of blood flow measure at 30 minute post capsaicin challenge to the blood flow measure prior to the capsaicin challenge.
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT01688739 |
20101267
2011-005600-15 |
|
March 13, 2012 |
May 1, 2013 |
|
September 20, 2012 |
November 6, 2017 |
|
- Research Site
Leuven, Belgium
|
|
| 91 |
NCT02764996 |
Completed |
An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine |
|
|
Interventional
|
Not Applicable |
- Mike O'Callaghan Military Hospital
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Reduction of migraine headache pain
|
26 |
All |
18 Years and older (Adult, Older Adult) |
NCT02764996 |
FWH20150084H |
|
December 2015 |
June 2017 |
June 2017 |
May 6, 2016 |
August 11, 2017 |
|
- Mike O'Callaghan Federal Medical Center
Nellis Air Force Base, Nevada, United States
|
|
| 92 |
NCT01388699 |
Completed |
Migraine and Endothelial Dysfunction |
|
|
Observational
|
|
- Charite University, Berlin, Germany
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- Endothelial Microparticles
- Levels of circulating Endothelial Progenitor Cells
- Digital pulse volume change
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT01388699 |
FF_NCRC_Migraine&ED |
|
October 2010 |
August 2011 |
December 2011 |
July 7, 2011 |
July 18, 2018 |
|
- Center for Stroke Research Berlin
Berlin, Germany
|
|
| 93 |
NCT01211795 |
Completed |
Topical Intra-Oral Ketoprofen for Migraine Prevention |
|
- Drug: topical intraoral ketoprofen gel
- Other: Placebo Gel
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change in number of migraine days per month
- Change in migraine severity
- Change in migraine duration
- Change in headache medication use
|
67 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01211795 |
IND 79,629 |
|
October 2009 |
June 2011 |
June 2011 |
September 30, 2010 |
June 8, 2011 |
|
- New York Medical College
Valhalla, New York, United States
|
|
| 94 |
NCT01542307 |
Completed
Has Results |
Normobaric Oxygen (NBO) Therapy in Acute Migraine |
|
- Biological: Oxygen
- Biological: Room air
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS)
- Change in Pain Score From 0-15 Minutes on the Visual Analogue Scale (VAS)
- Change in Pain Score From 0-60 Minutes on the Visual Analogue Scale (VAS)
- (and 4 more...)
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT01542307 |
2009P000380 |
|
July 2012 |
September 2015 |
September 2015 |
March 2, 2012 |
March 27, 2017 |
March 27, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 95 |
NCT02122237 |
Completed |
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial |
|
|
Interventional
|
Phase 3 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine frequency
- Migraine intensity
- Acute medication intake
- (and 2 more...)
|
14 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02122237 |
CB-1289 |
CATCHROMIG |
September 2013 |
April 2014 |
September 2014 |
April 24, 2014 |
May 28, 2015 |
|
- Roberta Baschi
Liège, Belgium
|
|
| 96 |
NCT00899379 |
Completed
Has Results |
Treatment of Multiple Attacks of Acute Migraine (0462-025) |
|
- Drug: rizatriptan benzoate
- Drug: Comparator: Placebo
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain Relief at 2 Hours During the First Migraine Attack Period
- Pain Relief at 2 Hours During the Second Migraine Attack Period
- Pain Relief at 2 Hours During the Third Migraine Attack Period
- Pain Relief at 2 Hours During the Fourth Migraine Attack Period
|
473 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00899379 |
0462-025
MK0462-025
2009_590 |
|
April 1995 |
January 1996 |
April 1996 |
May 12, 2009 |
April 3, 2015 |
July 15, 2010 |
|
|
| 97 |
NCT01184508 |
Terminated
Has Results |
A Study in Migraine Prevention |
|
- Drug: Placebo
- Drug: LY2300559
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change From Baseline to 12 Week Endpoint in the Number of Migraine Attacks
- Change From Baseline to 12 Week Endpoint in Severity of Migraine Intensity (Mild, Moderate, Severe)
- Change From Baseline to 12 Week Endpoint in Average Duration of Migraine Symptoms
- (and 7 more...)
|
87 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01184508 |
13313
I1N-MC-CDBE |
|
January 2011 |
April 2012 |
April 2012 |
August 19, 2010 |
September 12, 2018 |
September 12, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Long Beach, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fairfield, Connecticut, United States - (and 9 more...)
|
|
| 98 |
NCT01081795 |
Completed
Has Results |
A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine |
|
- Drug: Topiramate
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Pharmaceutical K.K.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6
- Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6
- Change From Baseline in Average Number of Monthly Headache Days at Month 1, 2, 3, 4, 5 and 6
- (and 7 more...)
|
387 |
All |
20 Years to 64 Years (Adult) |
NCT01081795 |
CR013681
JNS019-JPN-02 |
|
April 2007 |
January 2009 |
January 2009 |
March 5, 2010 |
July 2, 2013 |
May 6, 2013 |
- Bunkyo, Japan
- Chitose, Japan
- Hachioji, Japan
- (and 27 more...)
|
|
| 99 |
NCT02122757 |
Unknown † |
Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine |
|
|
Interventional
|
Phase 3 |
- University Hospital of Liege
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Migraine frequency
- Migraine intensity
- Acute medication intake
- (and 2 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02122757 |
CB-1300 |
ANODEM |
September 2013 |
September 2015 |
September 2015 |
April 25, 2014 |
May 28, 2015 |
|
- Roberta Baschi
Liege, Belgium
|
|
| 100 |
NCT02542605 |
Completed |
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients |
|
- Drug: AMG 334
- Drug: Placebo
- Drug: PACAP-38 Challenge Agent
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Occurrence of a migraine-like attack within 24 hours of challenge agent infusion
- Occurrence of a headache within 24 hours of challenge-agent infusion
- Treatment-emergent adverse events
- (and 3 more...)
|
33 |
All |
18 Years to 45 Years (Adult) |
NCT02542605 |
20140207 |
|
November 11, 2015 |
September 28, 2017 |
November 8, 2017 |
September 7, 2015 |
December 27, 2017 |
|
- Research Site
Anaheim, California, United States - Research Site
Leuven, Belgium - Research Site
Leiden, Netherlands
|
|
Create an RSS feed from your search for:
Download the search results for: